SQZ Biotechnologies Return on Tangible Equity 2020-2022 | SQZ

Current and historical return on tangible equity values for SQZ Biotechnologies (SQZ) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
SQZ Biotechnologies Return On Tangible Equity Historical Data
Date TTM Net Income Tangible Equity Return on Tangible Equity
2022-03-31 $-0.07B $0.11B -57.48%
2021-12-31 $-0.07B $0.12B -46.98%
2021-09-30 $-0.07B $0.13B -50.86%
2021-06-30 $-0.06B $0.15B -49.33%
2021-03-31 $-0.06B $0.17B -60.11%
2020-12-31 $-0.05B $0.13B -103.55%
2020-06-30 $-0.03B inf%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.087B $0.027B
SQZ Biotechnologies Company is a clinical-stage biotechnology company. It develops transformative cell therapies for patients with cancer, infectious diseases and other serious conditions. The company's prime product candidate consist SQZ-PBMC-HPV which is in clinical stage. SQZ Biotechnologies Company is based In Watertown, Massachusetts.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.597B 9.95
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
QIAGEN (QGEN) Netherlands $10.865B 17.15
Biohaven Pharmaceutical Holding (BHVN) United States $10.248B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.901B 48.18
Emergent Biosolutions (EBS) United States $1.599B 6.85
Myovant Sciences (MYOV) United Kingdom $1.236B 0.00
Zymeworks (ZYME) Canada $0.320B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.104B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00